Acepodia to Present Preclinical Data on its Gamma Delta T cell Therapy Candidate, ACE1831, at 2022 SITC Annual Meeting

Home : November 2022 : November 03, 2022 News : Acepodia to Present Preclinical Data on its Gamma Delta T cell Therapy Candidate, ACE1831, at 2022 SITC Annual Meeting
Acepodia to Present Preclinical Data on its Gamma Delta T cell Therapy Candidate, ACE1831, at 2022 SITC Annual Meeting
November 03, 2022 ALAMEDA, Calif., and TAIPEI, Nov. 3, 2022 /PRNewswire/ -- Acepodia, a clinical-stage biotechnology company developing first-in-class cell therapies with its unique antibody-cell conjugation (ACC) technology to address gaps in cancer care, today announced the upcoming poster presentation... https://www.prnewswire.com:443/news-releases/acepodia-to-present-preclinical-data-on-its-gamma-delta-t-cell-therapy-candidate-ace1831-at-2022-sitc-annual-meeting-301667249.html